多发性骨髓瘤全基因组测序揭示致癌通路通过多种机制受到体细胞突变靶向
该研究对来自CoMMpass的765例多发性骨髓瘤患者进行全基因组测序,利用naïve B细胞的启动子捕获Hi-C识别候选非编码驱动突变,发现CRE的CNV和PAX5增强子SNV等调控区突变可改变基因表达,并确定40个编码驱动基因(含11个新候选),显示同一通路可被编码和非编码突变靶向。
要点
- 765例MM患者全基因组测序,利用naïve B细胞启动子捕获Hi-C识别非编码驱动突变。
- CRE的CNV(如MYC)和PAX5增强子SNV等调控区突变可显著改变基因表达。
- 识别40个编码驱动基因(含11个新候选),同一通路可被编码和非编码突变靶向。
核心结论
- 多发性骨髓瘤的致癌通路可通过编码和非编码突变以多种机制受到体细胞突变靶向。
研究设计与样本
- 对来自CoMMpass的765例多发性骨髓瘤患者进行全基因组测序分析。
- 利用naïve B细胞的启动子捕获Hi-C识别cis调控元件(CRE)以搜索驱动突变。
主要发现
- 识别CRE的拷贝数变异(CNV)和PAX5增强子的单核苷酸变异(SNV)等调控区突变作为候选非编码驱动,可显著改变基因表达。
- 识别40个基因的编码驱动突变,包括11个新候选。
- IRF4和PRDM1以及BCL6和PAX5等对浆细胞分化关键的基因显示同一通路可被编码和非编码突变靶向。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying this complexity are incompletely understood. We report an analysis of the whole-genome sequencing of 765 MM patients from CoMMpass. By employing promoter capture Hi-C in naïve B-cells, we identify cis-regulatory elements (CREs) that represent a highly enriched subset of the non-coding genome in which to search for driver mutations. We identify regulatory regions whose mutation significantly alters the expression of genes as candidate non-coding drivers, including copy number variation (CNV) at CREs of MYC and single-nucleotide variants (SNVs) in a PAX5 enhancer. To better inform the interplay between non-coding driver mutations with other driver mechanisms, and their respective roles in oncogenic pathways, we extended our analysis identifying coding drivers in 40 genes, including 11 novel candidates. We demonstrate the same pathways can be targeted by coding and non-coding mutations; exemplified by IRF4 and PRDM1, along with BCL6 and PAX5, genes that are central to plasma cell differentiation. This study reveals new insights into the complex genetic alterations driving MM development and an enhanced understanding of oncogenic pathways.
引用
- Hoang PH, Dobbins SE, Cornish AJ, et al. Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 2018. PMID: 29654271. doi:10.1038/s41375-018-0103-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。